A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)
Phase 3
Completed
- Conditions
- Type 2 Diabetes MellitusHypercholesterolemia
- Registration Number
- NCT00110435
- Lead Sponsor
- Organon and Co
- Brief Summary
The purpose of this 10-week study is to compare the reduction in cholesterol following treatment with two different marketed drugs, in patients with type 2 diabetes mellitus and hypercholesterolemia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1229
Inclusion Criteria
- Men and women aged 18 to 79 years who have a confirmed diagnosis of type 2 diabetes mellitus with elevated cholesterol levels may be eligible to participate in a study to assess the efficacy and safety of the two marketed drugs.
Exclusion Criteria
- Type 1 Diabetes Mellitus
- Type 2 Diabetes Mellitus that is poorly controlled
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Percent reduction in LDL-C from baseline after 6 weeks of treatment
- Secondary Outcome Measures
Name Time Method Percent of patients attaining LDL-C <70 mg/dl after 6 weeks of treatment